Promontory Therapeutics

We are proud to continue our long-standing tradition of borderless innovation, and are thrilled to see this research collaboration come to fruition in a peer-reviewed publication in the Journal of Translational Medicine!

The Promontory team has been back at #ESMO2024 enjoying Barcelona and our learnings and interactions with clinicians and industry colleagues. Co-founder and COO Matthew Price, Chief Medical Officer Johan Baeck and our colleague in European medical affairs Jan D'haeyer M.D. have carried the flag and moved our program forward. Onward!

We are delighted to share the New Endpoints for Early-Stage Oncology Companies Panel from the 10th Annual Oncology Innovation Forum. Chaired by: Jeff Bockman, EVP Expert Advisor, Oncology, Lumanity Head, Oncology Center of Excellence, Lumanity Panellists: Colette Lipp, Director, Global BD Oncology & Immuno-Oncology, Merck KGaA, Darmstadt, Germany Jim Barlow, President & CEO, ImmunoGenesis, Inc. Matthew Price, Co-Founder, EVP & Chief Operating Officer, Promontory Therapeutics Inc. Nadim Ahmed, President & CEO, Cullinan Therapeutics, Inc. Raven Lin, Co-Founder & CEO, Pilatus Biosciences SA View here: https://lnkd.in/d8q8SAcz #OncologyEndpoints #EarlyStageOncology #CancerResearch #BiotechInnovation #Pharma #SachsForum #ASCO2024

It’s been a strong showing in Chicago today at the Sachs Associates forum, with co-founder Matthew Price speaking on the panel discussion around novel endpoints in #oncology , and Chief Medical Officer Johan Baeck presenting the company’s technology and clinical trials.

Our co-founder Matthew Price will discuss our company's use of novel clinical endpoints and biomarker tools in our Phase 2 studies during the #Sachs_OIF Forum on May 31st in Chicago. Matthew will be joined at the forum by our Chief Medical Officer Johan Baeck, who will present the company's development program later in the day. We're excited for Chicago! #oncologyresearch #ASCO2024

The recent IRA legislation was intended to reduce the costs of prescription drugs to patients. But a multitude of factors lying outside the scope of this legislation impacts the cost and quality of drugs reaching patients, in the US and beyond. ? Listen as Promontory COO, Matthew Price, joins Lori Ellis (Katz) and industry leaders in the latest episode of the Denatured Podcast to discuss broader systemic issues impacting U.S. healthcare, including the Inflation Reduction Act's effects on patient costs: https://lnkd.in/eu5PZdKA ? #biotech #oncologyresearch #ira #drugdevelopment #healthcare #policy

Thank you to BioSpace and Lori Ellis (Katz) for featuring Promontory COO, Matthew Price on the latest episode of the Denatured Podcast. The episode explores the unintended consequences of the IRA legislation on the innovation of small molecule therapeutics.? ? "The simplest way out of this question, and this problem, is to equalize the timeline to negotiation" for different therapeutic modalities under the IRA, said Matthew.?“I find it very healthy to see evidence now, not just in the dialogue and in the press, but in Congress, that there’s an effort made now under the EPIC Act before The House," to accomplish this. ? The speakers additionally explored and provided their individual experience around how the law has already affected the biopharma innovation ecosystem, and how it is likely to affect the future costs of healthcare in the US. Listen to the full podcast: https://lnkd.in/eCEEhkgd #biotech #oncologyresearch #ira #drugdevelopment #healthcare #policy

We are excited to announce reaching the target enrollment of 109 patients on our Phase 2 clinical trial of PT-112, in advanced, metastatic castration-resistant prostate cancer (mCRPC). In these patients, whose disease has progressed after three or more intended life-prolonging treatments, there is no broadly established solution for what is considered an immune-cold disease. We would like to thank our patients and study teams across 32 clinical sites in the United States and France — comprising our largest study of PT-112 to date — and we look forward to providing public data presentations later in the year. ? Learn more here: https://lnkd.in/ekct79jX. ? #biotech #biopharma #cancerresearch #ICD #smallmoleculeI_O #immunooncology #immunotherapy #ImmunoOnc #oncology

Promontory Therapeutics COO Matthew Price participated in a podcast episode about the #InflationReductionAct, drug pricing, patient experience and industry norms, hosted roundtable-style by BioSpace. ? Listen here: https://lnkd.in/e5D7Gapv. ? #DrugPricing #PatientCosts #HealthcareAffordability #AffordableMedicine #PatientAdvocacy #Healthcare #MedicationCosts

We look forward to connecting with our immuno-oncology peers at this week's IO360°?Summit in Brooklyn, NY. The impressive lineup of speakers will surely provide keen insights into next-generation approaches to challenges in cancer immunotherapy. We aim to be part of solving unmet needs that remain in #immunotherapy. ? Learn more here: https://io360summit.com/. ? The Conference Forum ? #IO360nyc #IO360 #biotech #biopharma #cancerresearch #ICD #smallmoleculeI_O #immunooncology #immunotherapy #ImmunoOnc #oncology